Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748879 | 0.93 | IGF1R (0.61) | IGF1RSYKRIPK1KDRGSK3B | |
| Trifluoroacetic Acid SCHEMBL1748780 | 0.92 | IGF1R (0.55) | IGF1RSYKRIPK1KDRGSK3B | |
| SCHEMBL1748413 | 0.88 | IGF1R (0.63) | IGF1RSYKRIPK1KDRGSK3B | |
| SCHEMBL1748781 | 0.88 | IGF1R (0.55) | IGF1RSYKRIPK1KDRGSK3B | |
| SCHEMBL5797045 | 0.85 | IGF1R (0.63) | IGF1RSYKRIPK1KDRGSK3B | |
| SCHEMBL1749006 | 0.85 | IGF1R (0.67) | IGF1RSYKRIPK1KDRGSK3B | |
| SCHEMBL1748415 | 0.82 | IGF1R (0.69) | IGF1RSYKEHMT2EHMT1DNMT1 | |
| SCHEMBL27687971 | 0.82 | IGF1R (0.61) | IGF1RSYKRIPK1DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL1748912 | 0.81 | IGF1R (0.56) | IGF1RSYKRIPK1KDRDRD2 | |
| SCHEMBL1748998 | 0.80 | GSK3B (0.37) | IGF1RKDRGSK3BEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968566-B2 | Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7528147-B2 | Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-05-05 | — | — | US | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K1 | IGF1R 817/4885SYK 379/4885RIPK1 392/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | IGF1R 817/4885SYK 379/4885RIPK1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.